focus -WSS

focus

author：explore 2025-09-27 19:29:20 - browse：4859

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Where are patients getting their prescriptions for GLP

hotspot

WSS

An innovative path out of biotech’s “valley of death”

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Intercept Pharmaceuticals sells itself for less than $1 billion

Researchers use wearables data and AI to predict preterm birth risk

Timeline: Special counsel's investigation into Trump's handling of classified documents

Novo acquires Inversago for up to $1 billion

Wikipedia

focus

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

After John Oliver segment, STAT readers share their opioid

After affirmative action ruling, medical educators look to 'holistic review'

Kim Kardashian sparks debate on benefits of full

Continuity nursing helped my family in our darkest PICU moments

Target recalls 2.2 million additional candles due to laceration, burn hazards

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA seeks to regulate lab

Anesthesiologist group: stop taking Ozempic before surgery

Menendez indictment could see pharma lose a key ally

Wikipedia

Covid vaccines: Private market messier than government rollout

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Kaiser Permanente unions announce official strike date

Novo acquires Inversago for up to $1 billion

FDA seeks to regulate lab

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

hotspot

focus

focus

Wikipedia